CTLA4 and rectal cancer: In addition to PD1/PDL1 targeting other immune checkpoint molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) in combination with RT represent exciting therapeutic approaches for rectal cancer.